Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update

Core Viewpoint - Mainz Biomed N.V. is shifting its focus to the pancreatic cancer detection business in the U.S. while engaging in strategic asset sales to enhance liquidity and explore growth opportunities [1][3]. Group 1: Strategic Transactions - The company entered into a securities purchase agreement for a $6.0 million private placement with investor David Lazar, structured in two tranches of $3.0 million each [2]. - The first tranche was completed on February 13, 2026, with the second tranche expected to close before April 15, 2026, pending stockholder approvals [2]. - Proceeds from the private placement will be used to fund ongoing operations, address liabilities, and maintain operational flexibility [2][3]. Group 2: Business Focus and Operations - Mainz Biomed is concentrating on developing its pancreatic cancer screening program in the U.S. while evaluating opportunities to sell its colorectal cancer screening assets [3]. - The company is in discussions with multiple parties interested in its colorectal cancer assets, which will help reduce operating expenses and extend its financial runway [3]. Group 3: Leadership Changes - David Lazar has been appointed as Chairman of the Board of Directors following the financing agreement [2][3]. Group 4: Product Portfolio - Mainz Biomed's flagship product is ColoAlert, a non-invasive early-detection test for colorectal cancer, marketed in Europe [5]. - The company is also developing PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection of biomarkers in blood and stool samples [5].